Charlevoix Disease

Charlevoix disease is a rare, inherited brain and nerve disorder. It begins most often in childhood. The problem starts in the part of the brain that controls balance and coordination (the cerebellum), the long nerve paths that control muscle tone and movement (pyramidal tracts), and the long nerves to the arms and legs (peripheral nerves). Because of this, a child first looks clumsy, wobbly, or late to walk. Over time, walking becomes stiff and shaky. Hands become weak and clumsy. Reflexes may be lost at the ankles, but the legs can feel tight or spastic. This condition happens when both copies of a gene called SACS do not work. The SACS gene normally makes a very large helper protein called sacsin that keeps nerve cells healthy. When sacsin is missing or faulty, nerve cells cannot keep their inner support system and energy systems stable, and they slowly get damaged. The disease progresses over many years. It is most common in people from the Charlevoix–Saguenay region of Québec in Canada but is now found in many countries. There is no cure yet, but diagnosis is possible and supportive care helps function and comfort. NCBImedlineplus.govOrphaTremor and Other Hyperkinetic Movements

Charlevoix disease, best known by its formal name ARSACS, is a genetic (inherited) neurological disorder. Children usually show signs between 2 and 5 years of age. They may fall often, walk with a wide base, or have trouble with fine hand tasks. Over time, muscle stiffness in the legs (spasticity) and damage to the long nerves in the limbs (peripheral neuropathy) make walking and balance even harder. Speech can sound slurred (dysarthria). Many people eventually need a wheelchair in adulthood, but thinking ability is usually good. Families from Québec’s Charlevoix–Saguenay region were first described, but ARSACS now is recognized worldwide. arsacs.comrarediseases.org

The root cause is biallelic (two-copy) mutations in the SACS gene on chromosome 13. SACS makes sacsin, a very large “chaperone-like” protein that helps other proteins fold and keeps nerve-cell structures healthy. When sacsin is missing or faulty, nerve cells—especially cerebellar Purkinje cells—struggle with protein quality control, mitochondrial health, and the scaffolding inside the cell (intermediate filaments). This drives the mix of ataxia, spasticity, and neuropathy seen in ARSACS. NCBIPMC+1Nature

Another names

Charlevoix disease has several names. Doctors often call it Autosomal Recessive Spastic Ataxia of Charlevoix–Saguenay (ARSACS). It is also called Charlevoix–Saguenay spastic ataxia, SACS-related ataxia, or spastic ataxia, Charlevoix–Saguenay type. “Autosomal recessive” means a person must inherit one nonworking SACS gene from each parent. “Spastic ataxia” describes stiff muscles (spasticity) and poor coordination (ataxia). The term “Charlevoix–Saguenay” points to the Québec region where many early patients were found. OrphaNCBI

Types

Doctors mainly talk about clinical forms based on age when symptoms start and speed of progression:

1) Classic early-childhood ARSACS. This is the common form. Babies and toddlers show unstable walking, frequent falls, and later stiff, awkward gait. It advances slowly across life. NCBI

2) Juvenile or adolescent onset. Symptoms begin in late childhood or teen years. The core pattern—ataxia, spasticity, and neuropathy—is the same but can progress a little later. PubMed

3) Adult-onset or “atypical” ARSACS. Some people develop symptoms in early adulthood. The triad is often present but may be milder or mixed. Because it is less typical, genetic testing is important to confirm the diagnosis. PubMed

Causes

Important note: The root cause of Charlevoix disease is always faulty SACS genes (one from each parent). The items below explain ways that cause shows up in the body—the biological changes and risk conditions that lead to the signs and symptoms.

1. Pathogenic variants in SACS. Changes in the DNA code (missense, nonsense, frameshift, splice) stop sacsin from working. NCBI

2. Loss of sacsin protein. Without sacsin, nerve cells lose a key quality-control helper. ScienceDirect

3. Cytoskeleton disorganization. Sacsin helps organize intermediate filaments inside cells; loss makes neurons fragile. medlineplus.gov

4. Mitochondrial stress. Energy handling in neurons becomes unstable, which harms long nerve fibers. ScienceDirect

5. Axonal transport problems. Cargo movement along nerve fibers is disturbed, so nerves degenerate. ScienceDirect

6. Purkinje cell dysfunction. The cerebellum’s main output cells struggle and shrink, causing ataxia. PubMed

7. Pyramidal tract injury. Damage to long motor pathways causes stiffness and brisk reflexes in legs. E-JMD

8. Peripheral neuropathy. Nerve damage to arms/legs adds weakness, numbness, and foot shape changes. E-JMD

9. Retinal nerve fiber layer thickening. Eye nerve fibers look thick on OCT, a helpful clue for diagnosis. PMCIOVS

10. Pontine and cerebellar changes on MRI. Typical “striped” lines in the pons and cerebellar atrophy appear. ACNR

11. Founder effect in Québec. Historic population factors increased the frequency of SACS variants in Charlevoix–Saguenay. Wikipedia

12. Consanguinity (in some families). Parents related by blood raise the chance the child inherits two faulty copies. (General genetics principle for recessive disorders.)

13. Compound heterozygosity. Two different SACS variants—one from each parent—can still cause disease. BioMed Central

14. Protein homeostasis imbalance. Cells cannot keep sacsin levels balanced; too little is harmful. National Ataxia Foundation

15. Neuroinflammation (secondary). Long-term nerve injury can trigger mild inflammation that worsens damage. (Inference from neurodegeneration models.)

16. Myelin abnormalities in nerves. Many people show a demyelinating-type neuropathy on nerve tests. E-JMD

17. Gait development stress. When children start walking, early cerebellar and pyramidal problems become visible. NCBI

18. Vision pathway involvement. Eye nerve fiber thickening may relate to abnormal myelination/hyperplasia. PMCIOVS

19. Autonomic features (some cases). Bowel, bladder, or sweating changes can occur due to nerve pathway involvement. BioMed Central

20. Genetic diversity worldwide. Many countries now report SACS variants; not limited to Québec families. Tremor and Other Hyperkinetic Movements

Symptoms

1. Unsteady walk (ataxia). The person walks wide-based and wobbly, with frequent falls. NCBI

2. Leg stiffness (spasticity). Legs feel tight; steps look stiff or scissoring. E-JMD

3. Poor coordination of hands. Fine tasks (buttons, keys, writing) are slow and shaky. PMC

4. Slurred or scanning speech. Words sound choppy or slow because of poor control of speech muscles. Wikipedia

5. Peripheral weakness. Distal muscles in the feet and hands lose strength. PMC

6. Numbness or tingling. Sensory loss from neuropathy causes odd feelings in feet/hands. PMC

7. Loss of ankle reflexes. Despite leg stiffness, ankle reflexes may be reduced or absent. BioMed Central

8. Foot deformity (high arch, hammertoes). Long-term weakness tightens foot shape. Wikipedia

9. Eye movement problems (nystagmus). Eyes may make quick, back-and-forth movements. Wikipedia

10. Fatigue with walking. Extra effort is needed to stay balanced and overcome stiffness. (Clinical experience pattern consistent with progressive ataxias.)

11. Hand tremor with action. Shaking gets worse when reaching for objects (intention tremor). (Common in cerebellar ataxias.)

12. Bladder urgency or other autonomic signs (some). Nerve pathway involvement can cause urinary symptoms. BioMed Central

13. Back curvature or posture change. Balance problems and muscle tone changes can alter posture over years. (Common secondary effect in chronic ataxias.)

14. Vision “fine-detail” issues (some). Most people see normally, but thick retinal fibers are a clue on testing. PMC

15. Gradual loss of walking independence in adulthood. Some people need a wheelchair later in life. Wikipedia

Diagnostic tests

A) Physical examination (at the clinic)

1. Neurologic exam for gait and balance. The doctor watches how you stand, walk, turn, and recover if pushed lightly. A wide-based, wobbly, stiff gait suggests the ARSACS pattern of ataxia plus spasticity. E-JMD

2. Tone and reflex testing. Increased muscle tone in the legs and brisk knee reflexes point to pyramidal tract involvement, while ankle reflex loss hints at peripheral neuropathy—this mixed picture is typical. E-JMDBioMed Central

3. Cranial nerve and eye movement exam. The doctor checks for nystagmus and smooth pursuit problems, common in cerebellar disease. Wikipedia

4. Strength and sensation testing. Distal weakness and reduced vibration or pinprick in feet/hands support neuropathy as part of the triad. PMC

5. Foot and spine inspection. High arches, hammertoes, and posture changes provide long-standing clues to chronic neuropathy and balance issues. Wikipedia

B) Manual bedside tests (simple office tests)

6. Finger-to-nose test. Overshoot or shaky touching of the nose shows limb ataxia from cerebellar dysfunction.

7. Heel-to-shin test. A wobbly or zig-zag slide along the shin shows leg coordination problems.

8. Tandem gait (heel-to-toe walking). Difficulty walking a straight line highlights truncal ataxia.

9. Romberg test. Extra sway with eyes closed suggests sensory involvement from neuropathy, which is common in ARSACS.

10. Timed 25-foot walk or 10-meter walk. A simple speed test to track progression and response to therapy over time.

C) Laboratory & pathological / genetic testing

11. Targeted genetic test for the SACS gene. Modern panels for “hereditary ataxia” or a single-gene SACS test can confirm the diagnosis by finding two pathogenic SACS variants. This is the gold standard. NCBI

12. Whole-exome or genome sequencing. If panels are negative or the picture is atypical, broader sequencing still often finds SACS variants and helps rule out look-alike conditions such as Friedreich ataxia or other hereditary spastic ataxias. NCBI

13. Basic blood tests to exclude mimics. Doctors may check vitamin E, B12, thyroid, liver, autoimmune markers, and infections. These do not diagnose ARSACS but help make sure nothing else is causing ataxia.

14. Creatine kinase (CK). Usually normal or only slightly raised; used mainly to exclude muscle disease in the workup.

15. Ophthalmic OCT (retinal scan). Optical Coherence Tomography measures the retinal nerve fiber layer (RNFL). In ARSACS, RNFL is often thickened—a very useful, noninvasive clue. PMCIOVS

D) Electrodiagnostic tests

16. Nerve conduction studies (NCS). These tests often show a sensorimotor demyelinating neuropathy, meaning the insulation on nerves is affected and signals slow down. This fits the ARSACS triad. E-JMD

17. Electromyography (EMG). EMG can show chronic nerve injury patterns in limb muscles, which support the diagnosis and exclude primary muscle disease. E-JMD

18. Evoked potentials (as needed). Visual or somatosensory evoked potentials can document slowed pathways in the brain or spinal cord if the history suggests it.

E) Imaging tests

19. Brain MRI for ARSACS “signs.” MRI often shows cerebellar atrophy (especially the upper vermis) and striking linear hypointense stripes across the pons. These changes are highly suggestive of ARSACS in the right clinical context. ACNRResearchGate

20. Spinal MRI or additional brain sequences (when needed). These help exclude other causes of spasticity or ataxia. Eye imaging (fundus photos) may show myelinated retinal nerve fibers in some people, another helpful clue.

Non-pharmacological treatments

1) Task-specific balance training (physiotherapy).
Purpose: Cut falls and improve steady walking.
Mechanism: Repeats real-world tasks (sit-to-stand, head turns, obstacle steps) to strengthen cerebellar compensation and postural reactions.
Benefits: Better stability, confidence, and safer ambulation.

2) Gait training with cues (physiotherapy).
Purpose: Improve step length and timing.
Mechanism: Visual lines, metronome beats, or therapist cueing entrain more regular steps and knee control despite ataxia/spasticity.
Benefits: Smoother, less variable gait; fewer near-falls.

3) Strengthening of antigravity and hip stabilizers (physiotherapy).
Purpose: Support joints and reduce energy cost of walking.
Mechanism: Progressive resistance for gluteals, quadriceps, tibialis anterior; closed-chain tasks to protect joints.
Benefits: Better transfers, stairs, and endurance.

4) Stretching program for spastic muscle groups (physiotherapy).
Purpose: Prevent contractures (Achilles, hamstrings, hip adductors).
Mechanism: Daily prolonged stretches (or night splints) reduce stiffness and keep joint range.
Benefits: Easier hygiene, seating, and brace fitting.

5) Orthoses and bracing (AFOs, KAFOs) (physiotherapy/orthotics).
Purpose: Control foot drop and knee hyperextension.
Mechanism: Hinged or solid braces stabilize ankle/knee and store/return energy.
Benefits: Safer walking, less tripping, more distance.

6) Assistive devices (cane, walker, wheelchair for distance).
Purpose: Fall prevention and energy conservation.
Mechanism: Adds contact points and support; wheelchair enables community mobility when fatigue is high.
Benefits: Independence with fewer injuries.

7) Functional electrical stimulation (FES) for foot-drop.
Purpose: Improve toe clearance.
Mechanism: Stimulates common peroneal nerve during swing phase.
Benefits: Fewer stumbles; sometimes more natural gait than an AFO.

8) Aquatic therapy (physiotherapy).
Purpose: Practice balance and strength with less risk.
Mechanism: Buoyancy lowers impact; water resistance strengthens safely.
Benefits: Confidence, endurance, joint comfort.

9) Treadmill or body-weight-supported treadmill training.
Purpose: Build rhythmic stepping and cardiovascular fitness.
Mechanism: Repetitive symmetrical stepping with harness support if needed.
Benefits: Longer walking distance, better cadence.

10) Coordination drills (physiotherapy).
Purpose: Reduce limb overshoot and shaking.
Mechanism: Slow, graded reach-to-target, Frenkel-style limb control training.
Benefits: Safer reaching, better hand use.

11) Spasticity positioning and seating program.
Purpose: Reduce pressure points and spasms in sitting.
Mechanism: Custom wheelchair seating, cushions, and posture supports.
Benefits: Comfort, skin protection, better breathing.

12) Speech therapy (dysarthria strategies).
Purpose: Clearer speech and less fatigue.
Mechanism: Breath support drills, pacing, loudness and articulation practice.
Benefits: Easier communication at school/work.

13) Swallow therapy and safe-eating strategies.
Purpose: Lower choking risk.
Mechanism: Texture changes, chin-tuck, small sips/bites, pacing, caregiver training.
Benefits: Fewer coughing episodes; better nutrition.

14) Hand therapy & adaptive tools (physiotherapy/OT).
Purpose: Improve daily tasks.
Mechanism: Weighted utensils, wrist supports, buttonhooks; graded fine-motor exercises.
Benefits: Independence in dressing, writing, eating.

15) Contracture prevention protocol (physiotherapy).
Purpose: Keep joints mobile long-term.
Mechanism: Home stretching, serial casting or night splints when needed.
Benefits: Easier mobility and hygiene; fewer surgeries.

16) Mind-body skills (relaxation, mindfulness, CBT).
Purpose: Lower anxiety, muscle co-contraction and pain.
Mechanism: Breathing, guided imagery, and cognitive reframing reduce stress-related tone.
Benefits: Better sleep, coping, and quality of life.

17) Fatigue management & energy conservation education.
Purpose: Do more with less exhaustion.
Mechanism: Activity pacing, planned rests, seating during tasks, prioritization.
Benefits: More school/work participation.

18) Falls-prevention home audit.
Purpose: Reduce injuries.
Mechanism: Remove loose rugs, add grab bars and night lights; teach safe transfers.
Benefits: Fewer fractures and ER visits.

19) Nutrition counseling (weight & bone health).
Purpose: Support muscle and bone; avoid constipation.
Mechanism: Adequate protein, calcium/vitamin D, fiber, and hydration; manage calories.
Benefits: Stronger bones, better energy.

20) Bladder/bowel routines.
Purpose: Manage urgency or constipation that worsen mobility.
Mechanism: Timed voiding, fiber, fluids, stool-softener plans.
Benefits: Comfort, fewer accidents/UTIs.

21) Pressure-injury prevention program.
Purpose: Protect skin in reduced mobility.
Mechanism: Reposition schedules, cushions, moisture control.
Benefits: Fewer wounds and infections.

22) Orthopedic foot-care and footwear.
Purpose: Prevent pain and falls from foot deformities.
Mechanism: Custom insoles, wide toe-box shoes, regular podiatry.
Benefits: More stable, less pain.

23) School/work accommodations.
Purpose: Keep learning and employment on track.
Mechanism: Extra time, accessible desks, speech-to-text, elevator access.
Benefits: Equal participation and success.

24) Genetic counseling & clinical-trial literacy (“education therapy”).
Purpose: Inform family planning and research options.
Mechanism: Explain autosomal-recessive inheritance, carrier testing, and registries.
Benefits: Informed choices; access to studies. NCBI

25) Community & peer-support engagement.
Purpose: Reduce isolation; share practical tips.
Mechanism: Patient groups and non-profits focused on ataxias/ARSACS.
Benefits: Emotional support, resources, advocacy. National Ataxia Foundation

---

Drug treatments

No medicine reverses ARSACS yet. Drugs are chosen to relieve spasticity, neuropathic pain, tremor, bladder symptoms, sleep problems, and to prevent complications.

1) Baclofen (oral; antispasticity).
Class: GABA_B agonist. Dose: often 5 mg 2–3×/day, titrating to 10–25 mg 3–4×/day as tolerated. Timing: regular, with slow titration. Purpose: loosen stiff muscles, reduce spasms. Mechanism: lowers excitatory transmission in spinal cord. Side effects: sleepiness, weakness; taper slowly to avoid withdrawal. (Severe cases may benefit from intrathecal baclofen) Wiley Online LibraryPMC

2) Tizanidine.
Class: α2-adrenergic agonist. Dose: start 2 mg at night; increase to 2–8 mg up to 3×/day. Purpose: spasticity relief. Mechanism: inhibits presynaptic motor neurons. Side effects: sedation, dry mouth, low BP; check liver enzymes.

3) Dantrolene.
Class: Direct skeletal-muscle relaxant. Dose: 25 mg/day → 25–100 mg 3–4×/day. Purpose: reduces spasticity. Mechanism: lowers Ca²⁺ release in muscle. Side effects: fatigue, rare liver toxicity—monitor LFTs.

4) Botulinum toxin type A (focal injections).
Class: Neuromuscular blocking biologic. Dose: individualized by muscle pattern (e.g., calves, adductors) every ~12 weeks. Purpose: relax focal overactive muscles to ease gait, hygiene, and pain. Mechanism: blocks ACh release at NMJ. Side effects: local weakness; rare spread effects.

5) Intrathecal baclofen (ITB) therapy.
Class: GABA_B agonist via pump. Dose: specialist-programmed (e.g., starting 25–100 µg/day). Purpose: treat severe spasticity when pills fail or cause sedation. Mechanism: targets spinal receptors directly with tiny doses. Side effects: pump/catheter issues, overdose/withdrawal risk—needs expert follow-up. Wiley Online LibraryPMC

6) Gabapentin.
Class: Neuropathic analgesic. Dose: 100–300 mg at night → up to 300–600 mg 3×/day. Purpose: burning/tingling pain, cramps. Mechanism: α2δ calcium-channel binding. Side effects: dizziness, somnolence.

7) Pregabalin.
Class: Neuropathic analgesic. Dose: 25–75 mg at night → 75–150 mg 2×/day. Purpose: neuropathic pain, sleep. Mechanism: α2δ modulation. Side effects: edema, weight gain, sedation.

8) Duloxetine.
Class: SNRI. Dose: 30 mg/day → 60 mg/day. Purpose: neuropathic pain and low mood/anxiety that can accompany disability. Mechanism: boosts serotonin/norepinephrine pain pathways. Side effects: nausea, BP changes.

9) Clonazepam.
Class: Benzodiazepine. Dose: 0.25–0.5 mg at night; max lowest effective. Purpose: tremor, severe cramps, sleep. Mechanism: GABA_A potentiation. Side effects: sedation, dependence—use sparingly.

10) Propranolol.
Class: Non-selective β-blocker. Dose: 10–20 mg 2–3×/day. Purpose: action tremor in some individuals. Mechanism: dampens peripheral tremor loops. Side effects: fatigue, low BP, asthma caution.

11) Baclofen + Tizanidine combination (careful).
Purpose: sometimes helps when one alone is partial. Caution: additive sedation/hypotension—requires close supervision.

12) Oxybutynin or mirabegron (if bladder urgency).
Class: Antimuscarinic / β3-agonist. Dose: Oxybutynin 2.5–5 mg 2–3×/day; Mirabegron 25–50 mg/day. Purpose: urgency/incontinence that worsens mobility. Side effects: dry mouth/constipation (oxybutynin), BP changes (mirabegron).

13) Sleep aids (melatonin first-line; low-dose trazodone if needed).
Purpose: improve sleep quality, which reduces daytime spasticity and fatigue. Caution: avoid heavy sedatives that increase falls.

14) Riluzole (off-label for cerebellar ataxia).
Class: Glutamatergic modulator. Dose: often 50 mg 2×/day (off-label). Purpose: may modestly help ataxia severity in some ataxias; evidence is mixed and not ARSACS-specific. Side effects: liver enzyme rise, nausea. (Discuss risk-benefit with a specialist.)

15) 4-Aminopyridine / Fampridine (off-label).
Class: Potassium-channel blocker. Dose: e.g., 10 mg 2×/day (extended-release; off-label). Purpose: sometimes improves gait in demyelinating/ataxia disorders; data in ARSACS are limited. Side effects: seizure risk—specialist oversight required.

Important: medication choices, doses, and combinations must be tailored by your neurologist/rehab team.

---

Dietary “molecular” supplements

(Helpful for general nerve and muscle health; none is proven to treat ARSACS specifically. Use only with your clinician’s approval to avoid interactions.)

1. Coenzyme Q10 100–300 mg/day: supports mitochondrial electron transport; may improve fatigue in some neurologic conditions.

2. Alpha-lipoic acid 300–600 mg/day: antioxidant; studied in neuropathy for glucose/oxidative stress control.

3. Vitamin D3 1,000–2,000 IU/day (or to level): bone health, fall risk reduction, immune balance.

4. Vitamin B12 1,000 µg/day (oral) if low or borderline: supports myelin and nerve function.

5. Vitamin B1 (thiamine) 50–100 mg/day: energy metabolism; deficiency worsens ataxia.

6. Vitamin E 200–400 IU/day: lipid antioxidant; very high doses can raise bleeding risk.

7. Omega-3 (EPA+DHA) 1–2 g/day: anti-inflammatory, supports nerve membranes.

8. Magnesium 200–400 mg/day (glycinate/citrate): may ease cramps/spasms; adjust for kidneys.

9. Creatine monohydrate 3–5 g/day: supports muscle energy store; may aid resistance training tolerance.

10. N-acetylcysteine (NAC) 600–1200 mg/day: antioxidant precursor; theoretical neuroprotection.

Note: evidence for these in ARSACS is indirect; choose only a few, track benefits/side effects, and review regularly.

---

Immunity-booster/regenerative/stem-cell” concepts

There are no approved immune-boosting or regenerative drugs for ARSACS. The items below are experimental concepts being explored in the broader ataxia/neurodegeneration field. They are not clinical recommendations.

1. Gene-replacement therapy (AAV-SACS). Concept: deliver a healthy SACS copy to neurons. Status: preclinical/early-concept; no established human dose yet.

2. Gene-editing/prime-editing for specific SACS variants. Concept: correct mutations at DNA level. Status: lab stage; significant safety hurdles.

3. Antisense oligonucleotides (ASOs). Concept: modify sacsin RNA processing for certain mutations. Status: mutation-specific research only.

4. Mitochondria-targeted antioxidants (e.g., MitoQ). Concept: reduce mitochondrial oxidative stress seen in sacsin loss. Status: experimental; mixed human data in other disorders. PMC

5. Autophagy/lysosome modulators. Concept: enhance cellular “cleanup” pathways affected by sacsin dysfunction. Status: preclinical. ScienceDirect

6. Cell-based therapies (neural/mesenchymal stem cells). Concept: support or replace damaged circuits. Status: investigational; no proven benefit in ARSACS; risks include immune reactions and procedure complications.

---

Surgeries

1. Intrathecal baclofen pump implantation.
   Procedure: A small pump is placed under the skin and a catheter delivers baclofen into spinal fluid.
   Why: For severe, generalized spasticity when pills are ineffective or too sedating; improves comfort, care, and sometimes gait. Wiley Online Library

2. Achilles tendon lengthening (gastrocnemius–soleus).
   Procedure: Surgical lengthening of tight calf tendons.
   Why: Corrects equinus (toe-walking), improves foot clearance and brace fitting.

3. Hamstring/adductor releases.
   Procedure: Lengthen tight thigh muscle tendons.
   Why: Reduce scissoring gait, ease hygiene, and improve sitting posture.

4. Foot deformity correction (e.g., cavovarus reconstruction).
   Procedure: Tendon transfers/osteotomies as needed.
   Why: Pain relief, plantigrade foot, better balance and brace tolerance in neuropathy.

5. Spinal fusion for scoliosis (selected cases).
   Procedure: Rods and screws straighten and stabilize the spine.
   Why: Treats painful or progressive curves that impair seating/breathing.

---

Prevention strategies

1. Falls prevention: remove tripping hazards; use aids early.

2. Contracture prevention: daily stretch plan; night splints if prescribed.

3. Skin protection: cushions, repositioning schedules, moisture control.

4. Bone health: vitamin D/calcium plus weight-bearing as able.

5. UTI prevention: hydration, timed voiding, bowel regularity.

6. Vaccinations: influenza, pneumococcal, COVID-19 to reduce infection setbacks.

7. Dental care: easier eating and less infection risk.

8. Respiratory health: treat colds early; airway clearance if weak cough develops.

9. Medication review: avoid heavy sedatives and drugs that worsen balance.

10. Genetic counseling: informed family planning to prevent recurrence. NCBI

---

When to see a doctor urgently or promptly

• Sudden worsening of walking, new frequent falls, or injuries.

• Painful spasms that block sleep or care, or new contractures.

• Choking, repeated chest infections, weight loss from swallowing issues.

• New numbness, weakness, bladder or bowel changes, or pressure sores.

• Concerns about medication side effects (extreme sleepiness, mood change, liver issues).

• Planning pregnancy or wanting family genetic counseling. NCBI

---

What to eat and what to avoid (simple, practical)

What to eat:

• A Mediterranean-style plate: vegetables, fruits, whole grains, legumes, nuts, olive oil.

• Adequate protein from fish, eggs, dairy, lean meats, or pulses to maintain muscle.

• Calcium and vitamin D sources (or supplements) for bone health.

• Fiber and fluids for regular bowels and bladder comfort.

• Small, frequent meals if fatigue lowers appetite.

What to avoid/limit:

• Excess alcohol (worsens ataxia and falls).

• Heavy sedatives and unnecessary polypharmacy (increase fall risk).

• Ultra-processed, very salty, or very sugary foods (inflammation, blood pressure swings).

• Crash diets or protein-poor plans (muscle loss).

---

Frequently asked questions

1) Is ARSACS the same as “Charlevoix disease”?
Yes. Charlevoix disease is a shorthand for ARSACS—the ataxia first described in Québec’s Charlevoix–Saguenay region. rarediseases.org

2) What gene is involved?
SACS. Both copies must be faulty (autosomal recessive) for the disease to appear. NCBI

3) What does the sacsin protein do?
Sacsin supports protein quality control, cytoskeleton health, and mitochondrial function in neurons. PMC+1

4) When do symptoms start?
Often between 2–5 years; progression is slow over decades. arsacs.com

5) How is ARSACS diagnosed?
Typical clinical features plus OCT RNFL thickening and brain MRI clues; confirmed by SACS genetic testing. PMCNCBI

6) Is there a cure?
Not yet. Care focuses on rehab, symptom control, and preventing complications. Research into gene-directed therapies is ongoing.

7) What specialists should be on the team?
Neurologist/physiatrist, physiotherapist, occupational and speech therapists, ophthalmologist, genetic counselor, and (when needed) orthopedic and spasticity-management specialists.

8) Will vision be lost?
Most people keep usable vision. OCT often shows thick RNFL—a diagnostic clue rather than a major vision problem. PMC

9) Can exercise help or harm?
Helps when supervised and paced. Focus on balance, stretching, and functional strengthening; avoid exhaustion and unsafe tasks.

10) Are there special diets?
No disease-specific diet; aim for balanced, bone-healthy, fiber-rich eating and adequate protein.

11) Are supplements required?
Only if you and your clinician agree. None are proven to treat ARSACS; use thoughtfully to avoid interactions.

12) What about pregnancy and ARSACS?
Many can have healthy pregnancies with planning. Genetic counseling can explain risks to children (autosomal-recessive inheritance). NCBI

13) Is intrathecal baclofen safe?
It can be very effective for severe spasticity in experienced hands. Pumps need regular follow-up to avoid overdose/withdrawal. Wiley Online Library

14) How is ARSACS different from Friedreich ataxia?
Different genes (SACS vs. FXN), different typical heart/diabetes risks (higher in Friedreich), and distinctive eye/MRI markers in ARSACS. Genetic testing separates them. NCBI

15) Where can families find trustworthy information and community?
National ataxia organizations and ARSACS-focused foundations provide education, support, and research updates. National Ataxia Foundation

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 10, 2025.

PDF Documents For This Disease Condition References